Mallinckrodt plc Reschedules Release of Fourth Quarter and Fiscal Year 2024 Financial Results to Thursday, March 13, 2025
Mallinckrodt plc (MNK), a global specialty pharmaceutical company, has rescheduled its fourth quarter and fiscal year 2024 financial results release to Thursday, March 13, 2025, before market open. The earnings conference call for investors will begin at 8:00 a.m. ET.
The company operates through two main segments: Specialty Brands, focusing on autoimmune and rare diseases in areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology, along with neonatal respiratory critical care therapies and gastrointestinal products; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.
Mallinckrodt plc (MNK), un'azienda globale di prodotti farmaceutici specializzati, ha riprogrammato il rilascio dei risultati finanziari del quarto trimestre e dell'anno fiscale 2024 a giovedì 13 marzo 2025, prima dell'apertura del mercato. La conferenza telefonica sugli utili per gli investitori inizierà alle 8:00 a.m. ET.
L'azienda opera attraverso due segmenti principali: Specialty Brands, che si concentra su malattie autoimmuni e rare in aree come neurologia, reumatologia, epatologia, nefrologia, pneumologia e oftalmologia, insieme a terapie critiche per la cura respiratoria neonatale e prodotti gastrointestinali; e Specialty Generics, che include farmaci generici specializzati e principi attivi farmaceutici.
Mallinckrodt plc (MNK), una empresa farmacéutica global especializada, ha reprogramado la publicación de sus resultados financieros del cuarto trimestre y del año fiscal 2024 para jueves 13 de marzo de 2025, antes de la apertura del mercado. La conferencia telefónica sobre ganancias para los inversores comenzará a las 8:00 a.m. ET.
La empresa opera a través de dos segmentos principales: Specialty Brands, que se centra en enfermedades autoinmunes y raras en áreas como neurología, reumatología, hepatología, nefrología, neumología y oftalmología, junto con terapias críticas de cuidado respiratorio neonatal y productos gastrointestinales; y Specialty Generics, que incluye medicamentos genéricos especializados e ingredientes farmacéuticos activos.
Mallinckrodt plc (MNK), 글로벌 전문 제약 회사,는 2024 회계연도 4분기 재무 결과 발표를 2025년 3월 13일 목요일로 재조정하였으며, 시장 개장 전에 발표할 예정입니다. 투자자를 위한 실적 컨퍼런스 콜은 오전 8시 ET에 시작됩니다.
회사는 두 가지 주요 부문을 통해 운영됩니다: Specialty Brands, 신경학, 류마티스학, 간학, 신장학, 호흡기학 및 안과와 같은 분야의 자가면역 및 희귀 질환에 중점을 두고 있으며, 신생아 호흡기 중환자 치료 요법 및 위장관 제품을 포함합니다; 그리고 Specialty Generics, 전문 제네릭 의약품 및 활성 제약 성분을 포함합니다.
Mallinckrodt plc (MNK), une entreprise pharmaceutique spécialisée mondiale, a reprogrammé la publication de ses résultats financiers du quatrième trimestre et de l'exercice 2024 pour le jeudi 13 mars 2025, avant l'ouverture du marché. La conférence téléphonique sur les résultats pour les investisseurs débutera à 8h00 ET.
L'entreprise opère à travers deux segments principaux : Specialty Brands, qui se concentre sur les maladies auto-immunes et rares dans des domaines tels que la neurologie, la rhumatologie, l'hépatologie, la néphrologie, la pneumologie et l'ophtalmologie, ainsi que sur les thérapies critiques de soins respiratoires néonatals et les produits gastro-intestinaux ; et Specialty Generics, qui comprend des médicaments génériques spécialisés et des ingrédients pharmaceutiques actifs.
Mallinckrodt plc (MNK), ein globales Unternehmen für Spezialpharmazeutika, hat die Veröffentlichung seiner Finanzzahlen für das vierte Quartal und das Geschäftsjahr 2024 auf Donnerstag, den 13. März 2025, vor Markteröffnung verschoben. Die Telefonkonferenz zu den Ergebnissen für Investoren beginnt um 8:00 Uhr ET.
Das Unternehmen operiert in zwei Hauptsegmenten: Specialty Brands, das sich auf Autoimmun- und seltene Krankheiten in Bereichen wie Neurologie, Rheumatologie, Hepatologie, Nephrologie, Pulmonologie und Augenheilkunde konzentriert, sowie auf kritische Atemtherapien für Neugeborene und gastrointestinalen Produkte; und Specialty Generics, das spezielle Generika und aktive pharmazeutische Wirkstoffe umfasst.
- None.
- None.
The conference call for investors will begin at 8:00 a.m. ET and can be accessed as follows:
- Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIf17087938ddc47079bf48d6d5e7c5687
- Audio-Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/igfp4swa
- On the Investor Relations page of the Mallinckrodt website: https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the
Investor Relations Contact
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-reschedules-release-of-fourth-quarter-and-fiscal-year-2024-financial-results-to-thursday-march-13-2025-302397490.html
SOURCE Mallinckrodt plc
FAQ
When will Mallinckrodt (MNK) release its Q4 and FY 2024 earnings?
What time is Mallinckrodt's (MNK) Q4 2024 earnings conference call?
What are the main business segments of Mallinckrodt (MNK)?
What therapeutic areas does Mallinckrodt's (MNK) Specialty Brands segment focus on?
